10月13日，Natera盘中下跌3.24%，报384.89美元/股，成交额3740.92万美元。
消息面上，摩根士丹利近日将Natera目标价从355美元上调至435美元，并维持增持评级，但股价在前期连续走强后仍出现回吐。
公司近期基本面催化持续，包括多癌早筛检测获得FDA突破性设备认定、Signatera在日本获批用于膀胱癌伴随诊断，且皮肤癌、乳腺癌等临床项目推进中。不过当前生物科技板块整体偏弱，Moderna同步下跌，短线情绪压制强于利好兑现。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.